Close Menu

Trovagene

Trovagene has appointed Paul Billings to its board of directors. Billings is currently chief medical officer at Life Technologies and is a member of Trovagene's scientific advisory board.

Paired Ends: Paul Billings

Premium

Trovagene has appointed Paul Billings to its board of directors. Billings is currently chief medical officer at Life Technologies and is a member of Trovagene's scientific advisory board.

Paul Billings has been appointed to Trovagene's board of directors, the company said this week.

Trovagene this week announced that its CLIA laboratory is now offering a test for the detection of the BRAF V600E mutations in cell-free DNA in urine.

NEW YORK (GenomeWeb News) – Trovagene today announced a clinical collaboration agreement with the University of Southern California for the use of the San Diego-based firm's cell-free DNA assays to genomically characterize metastatic colorectal cancers.

Trovagene is using RainDance Technologies' RainDrop Digital PCR system to develop and eventually run a cell-free transrenal BRAF mutation assay out of Trovagene's CLIA lab, the companies said this week.

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Trovagene today said that it has closed on a registered direct offering of $15 million of its common stock to an institutional investor at $7 per share.

Trovagene's stockholders have approved all six of the nominees for its board of directors, all of whom are current directors, to serve until the 2014 annual stockholder meeting.

NEW YORK (GenomeWeb News) – Cantor Fitzgerald on Monday initiated coverage of molecular diagnostics firm Trovagene with a Buy rating and a $10 price target on the company's stock.

NEW YORK (GenomeWeb News) – Trovagene said in a regulatory filing today that it has entered into a deal with Illumina to evaluate the possible integration of Trovagene's transrenal technology with Illumina's sequencing technology.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.